Home › Crohn's Disease › Ohio
Crohn's Disease clinical trials in Ohio
28 studies for Crohn's Disease are looking for participants at sites in Ohio.
Cities in Ohio
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03816345A Study of SL-325 in Crohn's Disease Patients
- Clinical Trial Site, Cincinnati
- Clinical Trial Site, Columbus
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Nov 12, 2026 · NCT07753850A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Nov 10, 2026 · NCT06430801Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Nov 4, 2026 · NCT06937099A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07577843A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 3
Ages 3 and older · All sexes · Updated Nov 3, 2026 · NCT06663332A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- The Children's Medical Center of Dayton, Dayton
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Nov 3, 2026 · NCT05923073A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07499232A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Nov 2, 2026 · NCT06233461A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- and 3 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Oct 28, 2026 · NCT06581328Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Dayton Gastroenterology - Beavercreek /ID# 284065, Beavercreek
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 27, 2026 · NCT07697456A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
- Medical Associates Research Group-Site Number: 8400063, Columbus
- OSU Wexner Medical Center-Site Number: 8400077, Columbus
- and 1 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 21, 2026 · NCT07184944An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
- University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
- Ohio Gastroenterology Group Inc.-8400006, Columbus
- and 5 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 21, 2026 · NCT07184931A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Cleveland Clinic - Cleveland /ID# 256453, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Oct 20, 2026 · NCT05995353A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Oct 9, 2026 · NCT06405087A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Childrens Medical Center, Dayton
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Oct 7, 2026 · NCT05509777Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Cincinnati /ID# 265589, Cincinnati
- The Ohio State University /ID# 265577, Columbus
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542Non-nutritive Sweeteners in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
RecruitingHealthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Sep 25, 2026 · NCT07769437Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
- Cleveland Clinic, Cleveland
Recruiting
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07680283Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
RecruitingPhase 3
Ages 2 and older · All sexes · Updated May 7, 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320Precise Infliximab Exposure and Pharmacodynamic Control
- Cincinnati Children's Hospital, Cincinnati
- Cleveland Clinic Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2/3
Ages 6 to 22 · All sexes · Updated May 5, 2026 · NCT05660746Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- OSU Inflammatory Bowel Disease Center, Hilliard
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Dec 10, 2025 · NCT06721962Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Recruiting
Ages 13 to 17 · All sexes · Updated Nov 21, 2025 · NCT07195123Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Cleveland Clinic Foundation, Cleveland
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2025 · NCT06670638From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.